April 19, 2023
The University of Cincinnati is one of 50 nationwide trial sites for a new clinical trial testing a new treatment for status epilepticus, the most severe and deadly form of epilepsy.
April 14, 2023
Physics World highlighted research led by the University of Cincinnati's Nalinikanth Kotagiri that shows a proof of concept for using engineered bacteria as an adapter to deliver targeted radionuclide treatment to tumors.
April 21, 2023
The University of Cincinnati's Alberto Espay will present Parkinson's disease research at the American Academy of Neurology's annual meeting April 22-27 in Boston.
April 21, 2023
Local 12 and WCPO highlighted the Imvax trial being hosted at the University of Cincinnati that is testing the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
May 19, 2023
The University of Cincinnati Cancer Center's Syed Ahmad, MD, is the national principal investigator for a phase 2 trial testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
May 26, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology (ASCO) annual meeting 2023, held in Chicago June 2-6.
December 6, 2022
Forbes highlighted research from the University of Cincinnati's Jeffrey Mills and Jeffrey Strawn examining factors behind the decision to begin or decline medication treatment for childhood anxiety disorders after cognitive behavioral therapy did not lead to improvement.
December 7, 2022
Psychiatry Advisor highlighted recent University of Cincinnati research that found in utero exposure to certain flame retardant chemicals may be a risk factor for developing anxiety symptoms in early adolescence.
October 4, 2022
University of Cincinnati researchers led by Alberto Espay and Andrea Sturchio published new research that supports the hypothesis that Alzheimer’s disease is caused by a decline in levels of a protein called amyloid-beta.
November 15, 2022
The University of Cincinnati's Jeffrey Strawn led research that found in utero exposure to certain flame retardant chemicals may be a risk factor for developing anxiety symptoms in early adolescence.